We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





AACC Advises Against Using Coronavirus Test CT Values to Guide COVID-19 Patient Care

By LabMedica International staff writers
Posted on 09 Jul 2021
Print article
Illustration
Illustration
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) has issued a public statement advising against the use of coronavirus test cycle threshold (Ct) values to guide COVID-19 treatment or public health efforts.

The medical community has become increasingly interested in the possibility of using coronavirus test Ct values to improve care for COVID-19 patients and overall management of the pandemic. When a patient gets a standard coronavirus test - known as a qualitative PCR test -Ct values are generated as part of the testing process. These values typically have an inverse relationship with the amount of virus in a patient specimen, with low Ct values indicating a high amount of virus in a sample, and high Ct values indicating the reverse. Because of this, some research has suggested that Ct values could potentially identify patients who have high viral loads and are at increased risk for serious disease. Other findings have also indicated that Ct values could potentially identify patients who aren’t infectious (i.e. those with low viral loads), which could improve contact tracing and outbreak tracking efforts.

However, conclusive data supporting the use of Ct values are lacking. In spite of these studies, many others in the medical community have cautioned against the use of Ct values, arguing that these values have numerous shortcomings and can’t reliably predict disease severity or transmissibility. In order to bring clarity to this issue, AACC members have released a statement that details the limitations of Ct values and recommends against their use. The statement emphasizes that, even though Ct values correlate with the amount of virus in specific specimens, studies have not actually established a relationship between Ct values and a patient’s overall viral load or infectiousness.

There are also numerous factors aside from the amount of virus in a specimen that can impact the Ct values generated during coronavirus testing. AACC’s statement lists all of these factors, which include variables such as patient age, the test instruments used, and even whether or not a patient blows their nose before sample collection. Even with these limitations, though, AACC’s statement acknowledges that clinicians might still want access to Ct values in certain circumstances. If clinical laboratories decide to report Ct values to clinicians who request them, the association recommends that labs include a prominent comment with every report explaining that the use of Ct values to guide patient management is discouraged and why.

“Along with the vaccines, coronavirus testing continues to play a critical role in managing the COVID-19 pandemic around the world,” said AACC President Dr. David G. Grenache. “AACC’s experts have therefore put together this document to provide much-needed guidance on this particular area of coronavirus testing, and to ensure that coronavirus PCR tests continue to be used in a way that best serves patient and public health needs.”

Related Links:
AACC

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)

New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.